Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas

^aFrom Nottingham University Hospitals, Department of Radiology (T.J.)
^bMedical Physics and Clinical Engineering (D.R., P.S.M.)
^cNottingham Biomedical Research Centre of the UK National Institute of Health Research (P.S.M.), Nottingham, UK
^dCardiff University, School of Medicine (T.C.), Cardiff, UK
^eWürzburg University, Institute for Diagnostic and Interventional Neuroradiology (M.W.-M.), Würzburg, Germany
^fVU University Medical Center, Department of Radiology & Nuclear Medicine (E.S.A.), Amsterdam, the Netherlands
^gLeeds Teaching Hospital, Department of Radiology (D.W.), Leeds, UK
^hAssistance Publique-Hôpitaux de Paris, Pediatric Radiology (R.C.), Paris, France
ⁱGustave Roussy and Paris-Sud University, Pediatric and Adolescent Oncology and Unite Mixte de Recherche (G.V., J.Grill), Villejuif, France
^jGreat Ormond Street Hospital, Haematology and Oncology Department (D.H.), London, UK
^kF. Hoffmann-La Roche (J.Garcia, G.Z.), Basel, Switzerland.

Please address correspondence to Daniel Rodriguez, MD, Medical Physics and Clinical Engineering, Nottingham University Hospitals, Derby Rd, Nottingham, NG7 2UH, UK; e-mail: daniel.rodriguez{at}nuh.nhs.uk